Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from HLS Therapeutics Inc ( (TSE:HLS) ) is now available.
HLS Therapeutics Inc., in collaboration with Amarin Corporation, announced the presentation of significant scientific data at the Canadian Cardiovascular Congress, emphasizing the therapeutic potential of Icosapent Ethyl and Eicosapentaenoic Acid. These presentations underscore HLS’s commitment to enhancing cardiovascular care and exploring the mechanistic effects of these compounds, potentially impacting the treatment of cardiometabolic conditions and inflammation-related endothelial functions.
The most recent analyst rating on (TSE:HLS) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.
Spark’s Take on TSE:HLS Stock
According to Spark, TipRanks’ AI Analyst, TSE:HLS is a Neutral.
The overall stock score of 52 reflects the company’s strong cash flow management and positive technical indicators, which are offset by significant challenges in profitability and valuation. The lack of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on TSE:HLS stock, click here.
More about HLS Therapeutics Inc
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted, and established branded pharmaceutical products in North America. The company primarily targets the central nervous system and cardiovascular therapeutic areas, leveraging the expertise of its seasoned management team.
Average Trading Volume: 15,654
Technical Sentiment Signal: Hold
Current Market Cap: C$166.1M
Learn more about HLS stock on TipRanks’ Stock Analysis page.